Efficacy is the primary factor in patients’ decisions to take antipsychotic medications, but weight gain is an important side effect that can also impact those decisions, explained Adam Simmons, director of clinical program management, Alkermes. Simmons was interviewed at the 175th Annual Meeting of the American Psychiatric Association, where he presented on the investigational drug ALKS 3831.
Efficacy is the primary factor in patients’ decisions to take antipsychotic medications, but weight gain is an important side effect that can also impact those decisions, explained Adam Simmons, director of clinical program management, Alkermes. Simmons was interviewed at the 175th Annual Meeting of the American Psychiatric Association, where he presented on the investigational drug ALKS 3831.
Transcript
Are there patient-reported outcomes indicating that more people will stay on therapy if they receive the benefits of olanzapine with less weight gain?
Yeah, interestingly, we did a survey of 500 patients living with schizophrenia being treated in outpatient clinics asking about what their preferences were for antipsychotic medications in general. Some of the feedback from that survey was that, first and foremost, efficacy was the most important factor for them taking a medication.
But when we asked about side effects, weight gain was one of the most important side effects for them to consider in taking a medication. Further to that, we asked about thresholds of weight gain, and about 80% of patients will go onto a medication, if that medication’s gonna cause about 5 pounds or less of weight gain.
But as you kind of go up the threshold and you start asking about 20 pounds or more, that’s where we know that for 70% of patients, they either absolutely won’t take a medication or it would seriously impact their decision. And with that, that number was even higher for females. So based on that survey as well as other information that’s been published in the literature, we know that weight gain is a major factor in people’s decision for choosing whether or not to take a certain antipsychotic medication.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More